中国肝细胞癌的动脉化疗:共识建议
Ming Zhao1,2,3, Zhi Guo4, Ying-Hua Zou5
1Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, China. drmingzhao@outlook.com.
Hepatology international
|October 21, 2023
概括
使用FOLFOX的肝动脉输液化疗 (HAIC) 对肝细胞癌 (HCC) 提供了生存益处. 这份专家共识提供了HAIC-FOLFOX在HCC治疗中的标准化建议,提高了安全性和有效性.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 干预性放射学 干预性放射学
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因.
- 肝动脉输液化疗 (HAIC) 是对HCC的有效治疗方法,具有局部控制和低系统毒性.
- 虽然HAIC-FOLFOX比标准治疗方法具有生存优势,但缺乏程序标准化.
研究的目的:
- 审查目前在HCC中治疗HAIC的现行做法.
- 制定专家共识陈述和建议,用于HCC的HAIC-FOLFOX.
- 为了解决HAIC程序周围缺乏标准化和争议的问题.
主要方法:
- 对HCC的HAIC最新证据的系统审查.
- 在中国广州召开专家共识会议 (2023年3月).
- 制定22项专家建议,涵盖候选人评估,程序细节,结果,并发症和管理.
主要成果:
- 累积的证据支持HAIC-FOLFOX在HCC中的生存益处.
- 目前缺乏标准化限制了HAIC-FOLFOX的安全和正确应用.
- 提出了22项专家建议,以规范HCC的HAIC治疗.
结论:
- HAIC-FOLFOX是HCC的一种有前途的治疗方法,提供了生存优势.
- 标准化建议对于HAIC-FOLFOX的安全和有效实施至关重要.
- 这些建议涵盖了HAIC-FOLFOX治疗的所有方面,从患者选择到并发症管理.
更多相关视频
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
483
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.4K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K